{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:28:38Z","timestamp":1793777318088,"version":"4.6.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100020806","name":"ANR","doi-asserted-by":"publisher","award":["ANR-23-CE17-0027-01"],"award-info":[{"award-number":["ANR-23-CE17-0027-01"]}],"id":[{"id":"10.13039\/100020806","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BRAINTWIN"},{"name":"MultiPOLA project","award":["OSIRIS25"],"award-info":[{"award-number":["OSIRIS25"]}]},{"name":"SiRIC CURAMUS programme","award":["12560"],"award-info":[{"award-number":["12560"]}]},{"name":"Horizon Europe Cofund SOUND.AI under the Marie Sk\u0142odowska-Curie","award":["101081674"],"award-info":[{"award-number":["101081674"]}]},{"name":"ERC Consolidator","award":["101087347"],"award-info":[{"award-number":["101087347"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Baseline biomarkers anticipating outcome in primary central nervous system lymphoma (PCNSL) are limited, and classical scores rely on clinical variables alone. We present a plasma proteomic framework for prognostic stratification of newly diagnosed PCNSL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Baseline plasma from 162 newly diagnosed PCNSL patients (French LOC network; training n=84; test n=78) was profiled using Olink Reveal (1,007 proteins). Consensus k-means clustering applied to the training proteome was projected to the test cohort, evaluated for immune-signature enrichment, and assessed by multivariable Cox regression. An elastic-net classifier predicted early treatment failure, evaluated by held-out and nested cross-validated AUC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clustering identified 2 proteomic states, Inflamed and Non-inflamed plasma, that replicated in the test cohort. The Inflamed state was enriched for pre-specified immune signatures, most strongly an Innate\/Inflammatory signature. High Innate\/Inflammatory scores marked shorter overall (OS) and progression-free survival (PFS) in training (log-rank P=.0014 OS, P=.0037 PFS) and test (P=5.4\u00d710\u207b\u2074 OS, P=.0014 PFS), remaining significant after adjustment for MSKCC class and sex (test OS HR 2.51, P=.0022). Combining signatures with clinical variables improved test discrimination, most clearly for PFS (C-index 0.68 vs.\u00a00.60). A supervised classifier predicted early treatment failure (PFS &amp;lt;\u00a09\u00a0months) at test AUC\u00a00.71, driven by the immune signatures rather than a whole-proteome search.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma proteomics identifies a reproducible Inflamed state in PCNSL associated with shorter OS and PFS that improves discrimination beyond clinical scores and stratifies the risk of early treatment failure. These findings support prospective evaluation of a focused innate-inflammatory plasma panel for risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag190","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:30:24Z","timestamp":1788521424000},"page":"2582-2596","source":"Crossref","is-referenced-by-count":0,"title":["Plasma proteomics for prognostic stratification in newly diagnosed primary central nervous system lymphoma"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7663-6819","authenticated-orcid":false,"given":"Tamara","family":"K\u00fcnzle","sequence":"first","affiliation":[{"name":"Paris Brain Institute (ICM), AP-HP Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9 , Paris,","place":["France"]},{"name":"LIX, \u00c9cole Polytechnique , Palaiseau,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Herzi","sequence":"additional","affiliation":[{"name":"Paris Brain Institute (ICM), AP-HP Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8978-7300","authenticated-orcid":false,"given":"Clara","family":"Boer Wigman","sequence":"additional","affiliation":[{"name":"Paris Brain Institute (ICM), AP-HP Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4863-2088","authenticated-orcid":false,"given":"Lucas","family":"Rincon de la Rosa","sequence":"additional","affiliation":[{"name":"Paris Brain Institute (ICM), AP-HP Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0934-5365","authenticated-orcid":false,"given":"Lucia","family":"Nichelli","sequence":"additional","affiliation":[{"name":"Paris Brain Institute (ICM), AP-HP Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-2507","authenticated-orcid":false,"given":"Isaias","family":"Hernandez-Verdin","sequence":"additional","affiliation":[{"name":"Paris Brain Institute (ICM), AP-HP Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7240-3437","authenticated-orcid":false,"given":"Angel","family":"Escamilla-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Department of Neuro-oncology, Institut de Neurologie, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5280-018X","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Paillassa","sequence":"additional","affiliation":[{"name":"Department of Hematology, CHU Angers , Angers,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-8937","authenticated-orcid":false,"given":"Renata","family":"Ursu","sequence":"additional","affiliation":[{"name":"Department of Neurology, H\u00f4pital Saint-Louis, AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0288-4607","authenticated-orcid":false,"given":"Stefania","family":"Cuzzubbo","sequence":"additional","affiliation":[{"name":"Department of Neurology, H\u00f4pital Saint-Louis, AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Davi","sequence":"additional","affiliation":[{"name":"Department of Biological Hematology, AP-HP Piti\u00e9-Salp\u00eatri\u00e8re , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-3240","authenticated-orcid":false,"given":"Magali","family":"Le Garff-Tavernier","sequence":"additional","affiliation":[{"name":"Department of Biological Hematology, AP-HP Piti\u00e9-Salp\u00eatri\u00e8re , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-2289","authenticated-orcid":false,"given":"Guido","family":"Ahle","sequence":"additional","affiliation":[{"name":"Department of Neurology, H\u00f4pitaux Civils de Colmar , Colmar,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6006-4917","authenticated-orcid":false,"given":"Laurence","family":"Schenone","sequence":"additional","affiliation":[{"name":"Department of Neuro-oncology, AP-HM, Aix-Marseille Universit\u00e9 , Marseille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Soussain","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut Curie , Saint-Cloud,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[{"name":"Department of Hematology, AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8424-2640","authenticated-orcid":false,"given":"Yannick","family":"Marie","sequence":"additional","affiliation":[{"name":"ICM Genomics and Sequencing Platform, Paris Brain Institute (ICM) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9182-5846","authenticated-orcid":false,"given":"Bertrand","family":"Mathon","sequence":"additional","affiliation":[{"name":"Paris Brain Institute (ICM), AP-HP Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1083-8379","authenticated-orcid":false,"given":"Clovis","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Paris Brain Institute (ICM), AP-HP Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2931-7522","authenticated-orcid":false,"given":"Caroline","family":"Houillier","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Paris Brain Institute (ICM), AP-HP Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kh\u00ea","family":"Hoang-Xuan","sequence":"additional","affiliation":[{"name":"Paris Brain Institute (ICM), AP-HP Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-4046","authenticated-orcid":false,"given":"Maks","family":"Ovsjanikov","sequence":"additional","affiliation":[{"name":"LIX, \u00c9cole Polytechnique , Palaiseau,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7220-2686","authenticated-orcid":false,"given":"Agust\u00ed","family":"Alentorn","sequence":"additional","affiliation":[{"name":"Paris Brain Institute (ICM), AP-HP Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026110401525044300_noag190-B1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"key":"2026110401525044300_noag190-B2","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026110401525044300_noag190-B3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume":"174","author":"Shiels","year":"2016","journal-title":"Br J Haematol"},{"key":"2026110401525044300_noag190-B4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades","volume":"20","author":"Mendez","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026110401525044300_noag190-B5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00401-016-1536-2","article-title":"Genomic characterization of primary central nervous system lymphoma","volume":"131","author":"Fukumura","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2026110401525044300_noag190-B6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2026110401525044300_noag190-B7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.annonc.2022.11.002","article-title":"Molecular and clinical diversity in primary central nervous system lymphoma","volume":"34","author":"Hern\u00e1ndez-Verdin","year":"2023","journal-title":"Ann Oncol"},{"key":"2026110401525044300_noag190-B8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Hoang-Xuan","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026110401525044300_noag190-B9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2023.11.010","article-title":"Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Ferreri","year":"2024","journal-title":"Ann Oncol"},{"key":"2026110401525044300_noag190-B10","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"key":"2026110401525044300_noag190-B11","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"2026110401525044300_noag190-B12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026110401525044300_noag190-B13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/noac246","article-title":"Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with\/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C","volume":"25","author":"Mishima","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026110401525044300_noag190-B14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026110401525044300_noag190-B15","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026110401525044300_noag190-B16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrneurol.2013.83","article-title":"Diagnosis and treatment of primary CNS lymphoma","volume":"9","author":"Korfel","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"2026110401525044300_noag190-B17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: from discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov"},{"key":"2026110401525044300_noag190-B18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026110401525044300_noag190-B19","doi-asserted-by":"publisher","first-page":"eadx2678","DOI":"10.1126\/science.adx2678","article-title":"A human pan-disease blood atlas of the circulating proteome","volume":"390","author":"\u00c1lvez","year":"2025","journal-title":"Science (1979)"},{"key":"2026110401525044300_noag190-B20","doi-asserted-by":"publisher","first-page":"9517","DOI":"10.1038\/s41467-025-64534-4","article-title":"Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes","volume":"16","author":"Kolijn","year":"2025","journal-title":"Nat Commun"},{"key":"2026110401525044300_noag190-B21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41467-025-67688-3","article-title":"Plasma protein profiling predicts cancer in patients with non-specific symptoms","volume":"17","author":"Wannberg","year":"2025","journal-title":"Nat Commun"},{"key":"2026110401525044300_noag190-B22","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1038\/s41591-024-03142-z","article-title":"Proteomic signatures improve risk prediction for common and rare diseases","volume":"30","author":"Carrasco-Zanini","year":"2024","journal-title":"Nat Med"},{"key":"2026110401525044300_noag190-B23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.medj.2024.03.007","article-title":"Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas","volume":"5","author":"Arffman","year":"2024","journal-title":"Med"},{"key":"2026110401525044300_noag190-B24","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3324\/haematol.2019.243626","article-title":"Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma","volume":"106","author":"Autio","year":"2021","journal-title":"Haematologica"},{"key":"2026110401525044300_noag190-B25","doi-asserted-by":"publisher","first-page":"1343109","DOI":"10.3389\/fimmu.2024.1343109","article-title":"Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"2026110401525044300_noag190-B26","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: an LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"key":"2026110401525044300_noag190-B27","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/neuonc\/noae029","article-title":"Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: an LOC network prospective multicentric study","volume":"26","author":"Rozenblum","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026110401525044300_noag190-B28","doi-asserted-by":"publisher","first-page":"e209527","DOI":"10.1212\/WNL.0000000000209527","article-title":"Prognostic value of CSF IL-10 at early assessment of induction chemotherapy in primary CNS lymphomas: a LOC network study","volume":"102","author":"Herzi","year":"2024","journal-title":"Neurology"},{"key":"2026110401525044300_noag190-B29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1182\/blood.2023022020","article-title":"Entirely noninvasive outcome prediction in Central nervous system lymphomas using circulating tumor DNA","volume":"143","author":"Heger","year":"2024","journal-title":"Blood"},{"key":"2026110401525044300_noag190-B30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4&lt;361::AID-SIM168&gt;3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"2026110401525044300_noag190-B31","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","article-title":"First-line treatment and outcome of elderly patients with primary Central nervous system lymphoma (PCNSL): a systematic review and individual patient data meta-analysis","volume":"26","author":"Kasenda","year":"2015","journal-title":"Ann Oncol"},{"key":"2026110401525044300_noag190-B32","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.22.00491","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study","volume":"40","author":"Houillier","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026110401525044300_noag190-B33","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026110401525044300_noag190-B34","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"2026110401525044300_noag190-B35","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1093\/nar\/gkr424","article-title":"Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood","volume":"39","author":"Lundberg","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2026110401525044300_noag190-B36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"2026110401525044300_noag190-B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v039.i05","article-title":"Regularization paths for cox\u2019s proportional hazards model via coordinate descent","volume":"39","author":"Simon","year":"2011","journal-title":"J Stat Softw"},{"key":"2026110401525044300_noag190-B38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"2026110401525044300_noag190-B39","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"2026110401525044300_noag190-B40","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026110401525044300_noag190-B41","doi-asserted-by":"publisher","first-page":"D687","DOI":"10.1093\/nar\/gkab1028","article-title":"The reactome pathway knowledgebase 2022","volume":"50","author":"Gillespie","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2026110401525044300_noag190-B42","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"2026110401525044300_noag190-B43","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2026110401525044300_noag190-B44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"2026110401525044300_noag190-B45","doi-asserted-by":"publisher","first-page":"vdab007","DOI":"10.1093\/noajnl\/vdab007","article-title":"Extent of radiological response does not reflect survival in primary central nervous system lymphoma","volume":"3","author":"van der Meulen","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2026110401525044300_noag190-B46","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1038\/srep06207","article-title":"Critical limitations of consensus clustering in class discovery","volume":"4","author":"\u0218enbabao\u011flu","year":"2014","journal-title":"Sci Rep"},{"key":"2026110401525044300_noag190-B47","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"2026110401525044300_noag190-B48","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"2026110401525044300_noag190-B49","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"2026110401525044300_noag190-B50","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag190\/71335683\/noag190.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/11\/2582\/71335683\/noag190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/11\/2582\/71335683\/noag190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:52:57Z","timestamp":1793775177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/11\/2582\/8831463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag190","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,23]]}}}